Congenital myasthenic syndromes (CMS) are a group of inherited diseases that affect synaptic transmission at the neuromuscular junction and result in fatiguable muscle weakness. A subgroup of CMS patients have a recessively inherited limb-girdle pattern of weakness caused by mutations in DOK7. DOK7 encodes DOK7, an adaptor protein that is expressed in the skeletal muscle and heart and that is essential for the development and maintenance of the neuromuscular junction. We have screened the DOK7 gene for mutations by polymerase chain reaction amplification and bi-directional sequencing of exonic and promoter regions and performed acetylcholine receptor (AChR) clustering assays and used exon trapping to determine the pathogenicity of detected variants. Approximately 18% of genetically diagnosed CMSs in the UK have mutations in DOK7, with mutations in this gene identified in more than 60 kinships to date. Thirty-four different pathogenic mutations were identified as well as 27 variants likely to be non-pathogenic. An exon 7 frameshift duplication c.1124_1127dupTGCC is commonly found in at least one allele. We analyse the effect of the common frameshift c.1124_1127dupTGCC and show that 10/11 suspected missense mutations have a deleterious effect on AChR clustering. We identify for the first time homozygous or compound heterozygous mutations that are localized 5 ′ to exon 7. In addition, three silent variants in the N-terminal half of DOK7 are predicted to alter the splicing of the DOK7 RNA transcript. The DOK7 gene is highly polymorphic, and within these many variants, we define a spectrum of mutations that can underlie DOK7 CMS that will inform in managing this disorder.
INTRODUCTION
DOK7 is a member of the DOK-family of proteins, which are adaptor molecules that act as downstream activators of receptor tyrosine kinases (1) . All members share common structural elements: an N-terminal pleckstrin homology (PH) domain, a phosphotyrosine-binding (PTB) domain and a C-terminal domain. DOK7 expression is largely restricted to the skeletal muscle and heart and is essential for neuromuscular junction formation and maintenance of the synaptic structure. The PTB domain of dimeric DOK7 interacts with the phosphorylated juxtamembrane region of the muscle-specific kinase (MuSK), promoting trans-autophosphorylation and activation of MuSK (1) . Subsequent phosphorylation of downstream targets results in dense clustering of acetylcholine receptors (AChRs) on the post-synaptic membrane, a pre-requisite for efficient neuromuscular transmission.
In congenital myasthenic syndromes (CMS), impairment of signal transduction at the neuromuscular junction gives rise to a group of clinically heterogeneous disorders that share the common feature of fatiguable muscle weakness (2 -4) . Different syndromes can exhibit different patterns of weakness, variable age of onset and, importantly, diverse responses to therapeutic treatments. Recessive mutations in the DOK7 gene have been shown to cause a CMS with a predominantly limbgirdle pattern of muscle weakness. Severity and age of onset * To whom correspondence should be addressed. Tel: +44-1865222311; Fax: +44-1865222402; Email: dbeeson@hammer.imm.ox.ac.uk # The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com Human Molecular Genetics, 2012, Vol. 21, No. 17 3765-3775 doi:10.1093/hmg/dds198 Advance Access published on June 1, 2012 varies in patients with DOK7 CMS, which most frequently presents in early childhood but in some cases may not present until adulthood (5 -13) . Unlike with most CMS, patients with DOK7 mutations do not respond well to conventional anti-cholinesterase treatments; indeed, this can often make the symptoms worse (6) (7) (8) 13 ). Many patients with DOK7 mutations harbour a common frameshift duplication c.1124-1127dupTGCC that is present in at least one allele, facilitating rapid diagnosis (6 -8) . While some patients are homozygous for this duplication, the majority are compound heterozygotes. The DOK7 gene is highly polymorphic with many rare variants, and so it is not always obvious as to which variant is pathogenic. For the patient, this may be critically important for a definitive diagnosis and for applications such as prenatal screening and a correct basis for therapy.
AChR clusters may be efficiently generated in cultured myotubes by the addition of agrin, and the process can be used as a model for postsynaptic specialization at the neuromuscular junction (14) . Overexpression of DOK7 in C2C12 myotubes efficiently promotes the formation of AChR clusters without the need for agrin (1) , whereas that of pathogenic mutations impairs this clustering of the AChR (6, 15) . We have used DNA screening and this experimental system to identify pathogenic mutations in a large cohort of patient samples referred to the Clinical Molecular Genetics laboratory in Oxford and to our research laboratory. The analysis shows a range of effects on AChR clustering, from a modest reduction in cluster number to almost complete absence of clusters, and shows differential complexity of AChR cluster form. In addition, we analyse a series of silent nucleotide variants that might affect the splicing of the DOK7 RNA transcript. The study provides a comprehensive analysis of the great variety of mutations that can underlie DOK7 CMS and identifies for the first time patients with DOK7 mutations exclusively in the N-terminal domains.
RESULTS

Mutations in DOK7
Patients with suspected CMS were screened for mutations within the seven exons of DOK7 and flanking regions and also within 2 kb of upstream genomic DNA containing the DOK7 promoter.
Mutations were detected in 72 patients derived from 64 different kinships (Supplementary Material, Table S1 ). Thirtyfour different mutations were identified (Fig. 1) . Twenty-seven additional variants were found (Fig. 2 ) that we believe are not pathogenic based on functional assays (see below), their occurrence in patients with alternative genetic diagnoses and their occurrence within the general population (http://www. 1000genomes.org/; http://www.ensembl.org/; https://esp.gs. washington.edu/drupal/). The commonly found mutation c.1124_1127dupTGCC (5 -13) was present homozygous or in at least one allele in 41/64 kinships ( 64%). Other homozygous deletion/insertion frameshift mutations were found in exon 7 (c.1138delG, c.1143delC, c.1143dupC, c.1296_ 1311del16, c.1339_1342dupCTGG, c.1511_1513delCTT). Mutation c.1511_1513delCTT results in the disruption of the termination codon, the loss of the C-terminal proline residue and read through of the 3 ′ -untranslated region for a further 182 amino acid residues. Functional analysis of frameshifting deletions in exon 7 shows that when the truncated DOK7 products are expressed in C2C12 myotubes, they partially retain the ability to induce AChR clustering. This was not the case when DOK7 harbouring mutations c.548_551delTCCT or c.601C.T located in exon 5 were expressed possibly because these would result in the loss of a nuclear export signal located between amino acid residues 240-249 (15) . While the majority of patients harbour at least one allele with a mutation in exon 7, we identified patients with missense variants in the N-terminal regions of DOK7 consistent with the recessive inheritance of the DOK7 CMS phenotype (Table 1) . Although sequences in the region 5 ′ upstream of the gene have been shown to be involved in governing DOK7 transcription (16) , to date we have not detected any CMS-causing mutations in these regions.
DOK7 CMS due to missense mutations in the N-terminal regions
Two children were identified with CMS due to pathogenic missense and frameshift variants exclusively in the N-terminal regions of DOK7. In brief, a 13-year-old boy, with consanguineous parents, had stridor (due to bilateral vocal cord Functional analysis of missense mutations/variants in the N-terminal region of DOK7
We analysed selected missense variants within the first five exons of DOK7 that were identified in suspected cases of DOK7 CMS. These included missense changes p.V139L in exon 4 that was found to be homozygous in a patient; and p.G109C located in exon 3 that was a compound heterozygote with frameshift mutation p.I198Tfs * X47 in exon 5. The remaining missense changes were all compound heterozygous with a frameshift in exon 7, except for variant p.S45L (Table 1) . We detected p.S45L as the only variant in a suspected CMS patient, but analysed it since it has been reported previously to underlie DOK7 CMS (5, 13) . Alignments of the missense variants/mutations with other species are shown in Figure 3 .
To assess the pathogenicity of the nucleotide changes, we used an AChR clustering assay. Overexpression of wild-type DOK7 in C2C12 myotubes promotes the clustering of AChRs, generating some quite complex structures, whereas mutant DOK7 generates fewer and sometimes less complex clusters (6) . Because C2C12 cells can be difficult to transfect, we created stable C2C12 myoblast cell lines by infection with retroviruses expressing either wild-type or mutant human DOK7. C2C12 cells infected with empty virus pBABE-PURO-EGFP were used as a control. Infected C2C12 myoblasts were differentiated to form myotubes, and AChR clusters were visualized using Alexa Fluor 594 a-bungarotoxin (a-BuTx-594). Most AChR clusters were simple plaque shapes, but others were more complex and were categorized as c-shaped, perforated or branched. An example of each category is shown in Figure 4A . Representative examples of stained myotubes for wild-type DOK7 and some of the mutants are shown in Figure 4B .
Wild-type DOK7 generated 250 AChR clusters/mm 2 ( Fig. 5A ) with almost 10% of the clusters being perforated or c-shaped (Fig. 5B) , and 4% showed even more complex branched shapes (Fig. 5C ). Nine of the DOK7 mutants (p.E3K, p.P31T, p.V139L, p.R158Q, p.G161R, p.G166R, p.G171D, p.G180A and 1124_1127dupTGCC) had a drastic effect on AChR clustering, significantly reducing the number of clusters to approximately background levels ( Fig. 5A ; one-way ANOVA P , 0.0001, Dunnett's multiple comparison test). p.G109C gave a less severe but still significant reduction of 75%, whereas p.T77M gave a non-significant reduction of 50%.
The complexity of AChR clusters generated by the DOK7 mutants was next analysed. p.E3K, p.T77M, p.G109C, p.R158Q, p.G161R and p.G171D all significantly reduced the percent of clusters that were c-shaped, perforated or branched. In addition, there was a significant reduction in branched but not c-shaped and perforated clusters with p.G166R, p.G180A and c.1124_1127dupTGCC ( Fig. 5B and C). It is of note that p.V139L also showed reduced complexity but this did not reach significance (see Discussion). One of the missense variants, p.S45L, did not have a significant effect on AChR cluster number or complexity ( Fig. 5A-C) .
We investigated whether the lack of clustering could be due to poor levels of expression of the mutant DOK7 proteins by western blotting, but all constructs gave robust expression that was much higher than that of endogenous DOK7 in C2C12, which was not detected by our western blot. A representative example is shown in Figure 6 . Thus, missense mutations in the N-terminal region of DOK7 are shown to affect the AChR clustering pathway.
Synonymous mutations within the DOK7 coding region
In the initial reports of the DOK7 neuromuscular junction synaptopathy, a number of patients were found in whom only one mutation within the coding region was identified (6 -8) . A later report (5) used analysis of genomic DNA and cDNA from muscle to identify RNA mis-splicing mutations. However, it is often not possible to have a muscle biopsy for analysis. We noted in four unrelated patients a frameshift mutation in one allele but only synonymous changes in the other allele (Table 2) . One synonymous variant is located within exon 1 (c.48C.T, p.G16G), and the other two silent variants are located within exon 4 (c.414C.T, p.L138L and c.513C.T, p.G171G). The synonymous change c.414C.T, p.L138L was identified in two unrelated patients. Analysis using splice site prediction software (www.fruitfly.org/ seq_tools/splice.htlm; Alamut splice site prediction software, Interactive Biosoftware) suggested that each of these silent variants has the potential to alter RNA splicing and to investigate we used exon trapping techniques. The exon trap vector pET01 contains two exons separated by an intron, which contains the multiple cloning site into which can be cloned one or more exons (plus flanking intron sequences) under investigation. The vector has intrinsic splicing ability, so that the intron(s) should be spliced out of the mRNA leaving the exons correctly spliced together. To analyse the splicing of c.48C.T in exon 1, exons 1 and 2 plus flanking intronic sequences of DOK7 were cloned into the multiple cloning site of pET01 to generate pETex1. The mutation was introduced by site-directed mutagenesis (pETc48). For the other two changes, exon 4 along with flanking intron sequences was cloned (pETex4) and mutations were 
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introduced (pETc414 or pETc513). The constructs were transfected into the muscle cell line TE671, RNA was extracted and cDNA corresponding to the mRNA region of interest was reverse transcribed. cDNA was amplified using primers specific for the vector exons and analysed by gel electrophoresis and sequencing. Wild-type exons were correctly spliced (Fig. 7A ). pETc48 produced a shorter transcript (Fig. 7A ) in which the whole of exon 1 was skipped, giving an in-frame deletion of 18 amino acid residues MTEAALVEGQVKLRDGKK (Fig. 7B) . The two silent changes in exon 4 also altered the splicing of RNA. pETc414 produced two different sized transcripts (Fig. 7A) . The larger transcript was correctly spliced but the shorter had a deletion of 94 nucleotides at the 5 ′ end of exon 4, which results in a frameshift (Fig. 7C) . Mutation c.513C.T created a cryptic splice site, resulting in a truncated exon 4 lacking the last 21 nucleotides of the exon (Fig. 7D) . Thus, each of these silent changes alters the splicing of the DOK7 RNA transcript and is predicted to be pathogenic.
DISCUSSION
Since the discovery in 2006 that mutations in DOK7 underlie a CMS associated with aberrant synaptic maturation and maintenance (6), it has become apparent that this syndrome forms a major subgroup of the CMS (2 -4). Within the cohort of CMS patients with confirmed genetic diagnoses studied within the host laboratory, 72 of 386 ( 18.6%) have mutations in DOK7. Screening of DOK7 for mutations and results from genome sequences (http://www.1000genomes. org/; http://www.ensembl.org/; https://esp.gs.washington.edu/ drupal/; https://esp.gs.washington.edu/drupal/) show this to be a highly polymorphic gene, with many sequence variants. Here, we have performed mutational analysis on a large patient cohort and functional studies on an extensive series of variants to delineate pathogenicity. We provide an extended list of defined mutations crucial for genetic diagnosis and counselling. In contrast with previous reports (6 -9,12,13) in which all patients have at least one mutation in the C-terminal domain defined by exon 7, we identify patients who are homozygous or compound heterozygotes for mutations within the N-terminal region PH and PTB domains and demonstrate their effect on the AChR clustering pathway.
DOK7 mutations in exon 7
The 34 different mutations we detected (Fig. 1) are located through the length of the coding region of the gene, but to date we have not detected mutations within the DOK7 promoter region (16) . The mutation c.1124_1127dupTGCC was commonly found in patients from both the Indian subcontinent and Europe and is present in 65% of DOK7 CMS kinships, which is lower than in previous reports in which the c.1124_1127dupTGCC allele was found in 14/15, 11/14, 4/6, 14/16 and 14/15, respectively (2,5 -7,13 ). The nuclear export signal located between amino acids 240 and 249 is thought essential for DOK7 to function, and there were no patients detected who harboured two truncations prior to this signal motif. However, a series of additional truncating mutations were found within exon 7, 3
′ to c.1124_1127dupTGCC, suggesting that there are residues at or near the C-terminal of DOK7 that are not essential for (at least) partial MuSK activation but do play a role in maintaining the synaptic structure. Mutations c.1143delC, c.1143dupC, c.1263dupC and c.1339_1342dupCTGG were all found homozygous in patients. c.1263dupC was found in 12 of 64 kinships and was the second most common mutation after c.1124_ 1127dupTGCC. Mutation c.1511_1513delCTT was found homozygous in two unrelated patients of Tamil origin in the Indian subcontinent suggesting that this mutation may be more common in the Tamil ethnic group. Mutation c.1511_1513delCTT leads to read through of the termination codon and predicted reading of an extra 182 amino acids, similar to mutation c.1513T.C that has been previously reported (3), and c.1504_1505insTA that also predicts a region of additional C-terminal residues. 
Mutations in the N-terminal regions
Truncations of DOK7 within the PH or PTB domains are almost certainly non-functional, as shown in functional studies (15) and as seen for the c.331+1G.T mutation that is predicted to cause the in-frame deletions of crucial function domains (5) and in vivo causes a lethal multiple pterygium syndrome (10) . It is more difficult to predict functional consequences of missense variants. We used the clustering of AChR in C2C12 myotubes induced by DOK7 as a functional assay for the DOK7 variants. In the AChR clustering assay, the only nucleotide change which we analysed that did not show a significant reduction in AChR cluster number was c.134C.T (p.S45L). The complexity of clusters was also not significantly different from those generated by wild-type DOK7. It has previously been suggested that p.S45L is pathogenic, since it was found in association with a known DOK7 exon 7 truncating mutation in three unrelated CMS patients (7, 12, 13) . However, no functional analyses were carried out in those reports. Although it is possible that p.S45L may have an effect on DOK7 not seen in our clustering assay, we consider this to be singlenucleotide polymorphism and not pathogenic: it is present as a heteroallelic variant in ENSEMBL:Watson, the T variant is observed at a frequency of 0.3% in the recent 1000Genome project and we have observed it in a series of suspected CMS patients who proved to have an alternative genetic diagnosis. Each of the DOK7 mutant proteins were expressed robustly in the myotubes, and so it is unlikely that any of the missense mutations impair DOK7 function through reduced expression, but all the additional missense variants that we analyse here, as well as the common duplication, show impaired function in the AChR clustering assay. All except p.T77M promoted significantly fewer AChR clusters than wild-type DOK7. Although p.T77M was not significantly different in cluster number, there was a marked and significant reduction in the complexity of the clusters that were generated. This, together with the 50% decrease in cluster number, indicates that the nucleotide change is likely to be pathogenic. It may be that along with mutations p.G109C and p.V139L, DOK7 
Mutations in the N-terminal domains that govern patient phenotype
Mutations p.G109C and p.V139L are identified here as missense mutations, in the N-terminal part of the protein, that are pathogenic but not lethal. Mutation p.G109C reduces cluster number less than all the mutations other than p.T77M, whereas p.V139L severely impairs AChR cluster number, but the complexity of the clusters generated is less affected than for many of the other mutations. The severity of DOK7 CMS shows considerable variation, even between patients harbouring the same homozygous mutations, or even between affected siblings (8) . The patients with solely N-terminal mutations show the characteristic DOK7 CMS phenotype of fatiguable proximal muscle weakness, near normal eye movements and a good response to salbutamol or ephedrine (7, 8) . It is not possible to extrapolate from only two cases, if these mutations underlie a more or less severe overall phenotype, though both these cases have a relatively mild phenotype.
Structural implications of the N-terminal region DOK7 mutations
The crystal structure of the DOK7 PH and PTB domains has recently been solved (17) and it is likely that the protein exists as a dimer upon binding to MuSK. We have used this crystal structure to gain some insight into the molecular basis of the pathogenicity of the mutations, which all reside within these two domains. To do this, we used Swiss PDB Viewer to investigate whether each mutation is predicted to induce a change in distance and/or a clash with other residues and used PyMOL to generate the figures. The predictions are summarized in Table 3 . Three of our mutations that abrogate AChR clustering in vitro, p.E3K, p.R158Q and p.G161R, are predicted to have a direct impact on binding of DOK7 to MuSK. Indeed, p.R158Q has been shown to impair the phosphorylation of both MuSK and the AChR b-subunit in C2C12 myotubes, and in that report, this mutation also reduced AChR clusters to background levels (15) . Arg158 in the PTB domain forms a salt bridge with the phosphate group on Tyr553 in the juxtamembrane domain of MuSK (16) , and the change to glutamine disrupts this salt bridge and would impair MuSK binding and activation. Glu3 forms a salt bridge with Arg555 of the MuSK peptide. The negative charge is important, as this residue is either a Glu or Asp across species. Our mutation p.E3K reverses the charge and therefore would disrupt this salt bridge and reduce binding of DOK7 and MuSK. Replacing the small residue Gly161 with the much longer residue arginine might sterically destabilize DOK7 and MuSK interactions. The distance between the side chains of Gly161 in DOK7 and Leu547 in the MuSK phosphopeptide is 4 Å , but this distance would be reduced to 3 Å when glycine is replaced with arginine (shown in Fig. 8A ). Dimerization of DOK7 (PH-PTB) is mediated mainly by invariant residues 28-35 in the PH domain that interact with their counterparts within the PH domain of the other protomer (i.e. the other protein in the dimer). One mutation, p.P31T, lies within this b2-b3 loop. Pro31 is in van der Waals contact with Phe210
′ (the apostrophe indicates Phe210 in the other protomer of the dimer) with the aromatic ring of phenylalanine stacked against the proline ring. Altering the proline to a threonine would disrupt this stacking and would likely destabilize dimerization (Fig. 8B) . Another of our mutations, p.G109C, would also affect dimerization, since this residue is in van der Waals contact with V32 ′ , a residue within the b2-b3 loop which is situated at the 'linchpin' position of the dimer. Mutation of the glycine to the larger residue cysteine is predicted to sterically hinder dimer formation (Fig. 8C) . For mutation p.T77M, Met77 clashes with W19 in the same protomer (Fig. 8D) and it has been suggested that p.G180A might generate unfavourable backbone torsion angles (17) . p.G171D might also affect protein folding, since Asp171 intrudes into a region of hydrophobicity formed by residues Trp152, Leu157, Trp178 and Phe182 (Fig. 8E) . Mutations in residues that are at the surface of the molecule (p.V139L and p.G166R) have a less clear pathogenic mechanism but may affect binding of DOK7 to other as yet unknown ligands.
Cryptic RNA splice sites due to synonymous mutations within the coding region A feature of the current polymerase chain reaction (PCR)-based methodology of mutational screening of DOK7 is the number of patients in whom only one mutation has been identified (6 -8,12) . Mutations in donor and acceptor splice sites in the DOK7 gene have been described in CMS patients (5, 12) and screening of cDNA has shown that in some cases there are additional mutations, probably within the introns, that cause splicing errors (5), but cDNA is not always available for study. Here, we have identified three different silent mutations in the N-terminal region that generate cryptic splice sites. The mutation c.48C.T in exon 1 generates a cryptic donor splice site GT, resulting in skipping of exon 1. This corresponds to an in-frame deletion of the first 18 amino acids including the methionine start site. The next methionine that is predicted to serve as a translation start site (using NetStart 1.0 prediction server) is amino acid 38. Loss of the first 37 amino acids is likely to reduce the association of DOK7 with the membrane phosphoinositides, since residues at positions 18, 20 and 22 are thought to be important for this interaction (17) . The putative nuclear localization signal that resides within the PH domain (15) might also be affected, although further experiments are required to verify this. Mutation c.414C.T, identified in two unrelated index cases, generates two different transcripts, one that is correctly spliced and a shorter one that is missing the first 94 nucleotides, thereby causing a frameshift which would be deleterious. In this shorter transcript, nucleotide pair AG that is located 10 and 11 nucleotides downstream of the mutation becomes an acceptor splice site. The third silent mutation in exon 4, c.513C.G, introduces a donor splice site leading to an in-frame deletion of the last seven amino acid residues from this exon. Two of these residues, Thr173 and Arg174, coordinate with p.Y553 in MuSK and are therefore crucial in the pathway leading to NMJ formation/stabilization. We checked if mutation c.512G.A, p.G171D affects splicing by exon trapping techniques, but no abnormal transcripts were seen (data not shown). The sequence around Gly171 seems particularly prone to mutations with missense mutations p.G171D (reported here) and p.G171R and p.G172R identified (12) .
Implications for DOK7 CMS
DOK7 is a highly polymorphic gene, and this must be taken into account when screening patients for mutations. The recent release of data from the 1000Genome project provides valuable information about polymorphisms that will be useful in determining the pathogenic status of nucleotide changes in patients. However, in recessive disorders, it is often not possible to differentiate between rare variants with no functional consequence and pathogenic alleles. Moreover, computer modelling is not yet sufficiently advanced to reliably predict pathogenicity. Similarly, we show here that coding changes that may apparently segregate with disease (7,12,13) may not be pathogenic, and conversely, that synonymous changes may not be benign. By utilizing the clustering of AChR in C2C12 myotubes induced by the infection of mutant DOK7-expressing vectors we have a functional assay that can be used to determine pathogenicity of DOK7 mutations. The impaired clustering seen in this assay is likely to reflect the instability of the neuromuscular junctions in vivo. It is frequently important to define a CMS at the molecular level to ensure appropriate therapy; for instance, DOK7 CMS patients show a slow but dramatic improvement with ephedrine or salbutamol but may worsen with cholinesterase inhibitors (7, 8, 18) . Here, we provide data on 61 different variants within DOK7, identifying 34 as pathogenic. We would also suggest that genetic diagnosis requires the screening of all the DOK7 exons since mutations restricted to the N-terminal 
Plasmids and constructs
For AChR clustering experiments, human DOK7 encoding cDNA was cloned into pBABE-PURO-EGFP, a plasmid that has an internal ribosomal entry site site before enhanced green fluorescent protein (EGFP) such that DOK7 and EGFP are expressed as two separate proteins. For RNA splicing experiments, exons 1 and 2, or exon 4, and flanking intronic sequences were amplified and cloned into the multiple cloning site of the exon trap vector pET (MoBiTec). Mutations were introduced by site-directed mutagenesis using QuickChange (Stratagene).
Cell lines
TE671, a rhabdomyosarcoma with muscle-like properties (19) , Phoenix eco cells and C2C12 cells were purchased from ATCC. TE671 and Phoenix eco cell lines were maintained at 378C in Dulbecco-modified essential medium (DMEM; Sigma-Aldrich) supplemented with 10% foetal calf serum (FCS) (PAA Cell Culture Ltd) and 100 U/ml each of penicillin G and streptomycin (PS) purchased from Invitrogen. C2C12 cells were maintained at 378C in DMEM supplemented with 15% FCS and PS and were fused to form myotubes in fusion medium (DMEM containing 2% FCS and PS).
Transfection of TE671 cells
TE671 cells were seeded at 2 × 10 5 cells/well in 6-well plates and the following day were electroporated with a total of 3 mg of DNA per well using the Neon electroporator (Invitrogen).
Generation of retroviruses and infection of C2C12 myoblasts
T25 tissue culture flasks were seeded with 2 × 10 6 Phoenix eco cells and were transfected with 15 mg of pBabe-PURO-EGFP-DOK7 constructs using polyethyleneimine. The following day, the cells were reseeded into a T75 flask with 6 ml of growth medium, and after a further 2 days, the conditioned medium was harvested, centrifuged to remove cell debris and stored at 2808C. C2C12 myoblasts were infected overnight with neat retrovirus containing 8 mg/ ml of polybrene. The following day, the medium was replaced with growth medium and 2.5 mg/ml of puromycin was added 72 h after infection.
Analysis of AChR clustering
To visualize AChR clusters, C2C12 myotubes were incubated with a-BuTx-Alexa Fluorw-594 (a-BuTx-594, Invitrogen) diluted 1:1000 in fusion medium for 1 h at 378C. Cells were washed three times in fusion medium, fixed in fusion medium containing 3% formaldehyde and stored in phosphate buffered saline at 48C. Images were acquired using an Olympus IX71 fluorescence microscope with software from Digital Pixel. Length and number of clusters were measured using Volocity (Improvision). Only clusters that were longer than 3 mm were included in the analyses.
Western blot analysis
C2C12 myotubes were harvested from 6-well plates and resuspended in cold lysis buffer containing mammalian protease inhibitor cocktail (Sigma). Lysates were extracted by rotating for 1 h at 48C followed by centrifugation. Protein concentration was measured using a BCA kit from Pierce, and 15 mg was subject to SDS-PAGE. After blotting onto nitrocellulose, DOK7 was visualized using rabbit anti-DOK7 (Santa Cruz), anti-rabbit-horse radish peroxidase (Dako) and ECL TM (GE Healthcare).
RNA splicing
The exon trap cloning vector kit was obtained from MoBiTec. pET constructs harbouring the respective DOK7 sequence variants were transfected into TE671 cells, and 48 h later, the RNA was extracted and was reverse transcribed into cDNA (Retroscript, Ambion). cDNA was amplified using vectorspecific primers, and the amplicons were run on agarose/ TBE gels, visualized under UV/ethidium bromide and then gel purified and sequenced.
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